Tris Pharma Reports the Availability of Dyanavel XR (amphetamine) Tablets for Attention Deficit Hyperactivity Disorder

Shots:

Dyanavel XR has been approved in the US for ADHD in patients aged ≥6yrs. in 2015 & now available as extended-release tablets for oral use
The results from the P-III study of Dyanavel XR vs PBO in adults with ADHD which were published in the Journal of Clinical Psychiatry showed an improvement in mean PERMP-T scores averaged across all measured post-dose time points
Additionally, Dyanavel XR extended-release tablets showed an improvement in ADHD symptoms within 1 hr. that persisted through 13 hrs. after QD dosing and were bioequivalent to Dyanavel XR extended-release oral suspension CII while Dyanavel XR improved ADHD symptoms as soon as 30 min. after dosing, based on the separate exploratory study

Ref: PR Newswire | Image: Tris Pharma